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Ahmar Aziz1,2, Jeffrey H. Spiegel4, Vladimir A. Botchkarev1,2,3 and Andrey A. Sharov1,2
Chemotherapy has severe side effects in normal rapidly proliferating organs, such as hair follicles, and causes
massive apoptosis in hair matrix keratinocytes followed by hair loss. To define the molecular signature of hair
follicle response to chemotherapy, human scalp hair follicles cultured ex vivo were treated with doxorubicin
(DXR), and global microarray analysis was performed 3hours after treatment. Microarray data revealed changes in
expression of 504 genes in DXR-treated hair follicles versus controls. Among these genes, upregulations of
several tumor necrosis factor family of apoptotic receptors (FAS, TRAIL (tumor necrosis factor–related apoptosis-
inducing ligand) receptors 1/2), as well as of a large number of keratin-associated protein genes, were seen after
DXR treatment. Hair follicle apoptosis induced by DXR was significantly inhibited by either TRAIL-neutralizing
antibody or caspase-8 inhibitor, thus suggesting a previously unreported role for TRAIL receptor signaling in
mediating DXR-induced hair loss. These data demonstrate that the early phase of the hair follicle response to
DXR includes upregulation of apoptosis-associated markers, as well as substantial reorganization of the terminal
differentiation programs in hair follicle keratinocytes. These data provide an important platform for further
studies toward the design of effective approaches for the management of chemotherapy-induced hair loss.
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INTRODUCTION
Hair loss (alopecia) is a common side effect of many chemo-
therapeutic treatment protocols and is one of the most dis-
tressing aspects of cancer therapy. Because of the rapid
proliferation of hair matrix keratinocytes during hair shaft
production, the hair follicle represents a ‘bystander’ target for
many chemotherapeutic agents (Paus and Cotsarelis, 1999;
Botchkarev, 2003; Trueb, 2009; Paus et al., 2013). Despite
significant advances in understanding the mechanisms of the
hair follicle response to chemotherapeutic agents achieved
within the last decade (Botchkarev et al., 2000; Sharov et al.,
2003; Sharov et al., 2004; Hendrix et al., 2005; Bodo et al.,
2007; Jimenez et al., 2008; Bodo et al., 2009), no effective
treatment is currently available to prevent or retard this
devastating side effect of anti-cancer therapy.
To study the effects of chemotherapeutic agents on the hair
follicle, a number of experimental models have been pro-
posed (Jimenez and Yunis, 1992; Paus et al., 1994; Bodo
et al., 2007). In a C57BL/6 mouse model for chemotherapy-
induced hair loss (Paus et al., 1994; Lindner et al., 1997),
cyclophosphamide administration caused rapid increase in the
p53 protein in hair matrix keratinocytes, followed by massive
apoptosis, whereas genetic p53 ablation resulted in complete
resistance of the hair follicles to chemotherapy (Botchkarev
et al., 2000). Fas (APO-1, CD95) as a p53 target is also
involved in mediating apoptosis in the hair matrix keratino-
cytes and melanocytes during hair follicle exposure to cyclo-
phosphamide (Lindner et al., 1997; Sharov et al., 2003; 2004).
In contrast to p53 and its target genes, members of the fibro-
blast growth factor (FGF) family, including keratinocyte growth
factor, as well as pharmacological modulator of the heat-shock
proteins geldanomycin show relative protective effects in rodent
models of chemotherapy-induced hair loss (Danilenko et al.,
1995; Jimenez et al., 2008; Bodo et al., 2009).
During chemotherapy, the DNA damage response is regu-
lated at several levels, including involvement of the response
sensors, transducers, and effectors, which operate in a stage-
dependent manner to induce apoptosis, cell cycle arrest, or
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senescence in target cells (reviewed in Jackson and Bartek,
2009; Paus et al., 2013). Analyses of the kinetics of the cellular
response to chemotherapy reveal that anti-cancer drugs induce
apoptosis in tumor cells within several hours after in vivo
administration (Meyn et al., 1995a, b). Cyclophosphamide
treatment in mice also induces apoptosis in rapidly proli-
ferating hair matrix keratinocytes within 24 hours after intra-
peritoneal administration (Lindner et al., 1997; Botchkarev
et al., 2000; Sharov et al., 2003; Sharov et al., 2004).
In a recently developed an ex vivo human model for
chemotherapy-induced hair loss, it was shown that the
cyclophosphamide derivative 4-hydroperoxycyclophospha-
mide induces apoptosis in isolated human hair follicles,
followed by their dystrophy, in a manner that resembles the
follicular response to cyclophosphamide in the C57BL/6
mouse in vivo model (Bodo et al., 2007). In this model,
microarray analyses of the relatively advanced stage (48 hours)
of the hair follicle response to chemotherapy reveal the
changes in expression of more than 400 genes including
several growth factors (FGF-18, IL-8, and so on), apoptotic
regulators (BAX, MDM2, and so on) and adhesion/extra-
cellular matrix–associated molecules (CTNND2, GPC6, and
so on), suggesting their involvement in chemotherapy-induced
hair loss (Bodo et al., 2007).
However, the mechanisms underlying the early phase of the
hair follicle response to chemotherapy remain unclear. In this
article, we use a global microarray profiling approach to
define the molecular signatures of the early phase of response
of hair follicles to chemotherapy treatment ex vivo. We show
here that the early phase of the hair follicle response to
chemotherapy is far more complex than it was previously
appreciated and includes upregulation of not only apoptosis-
associated genes but also marked reorganization of the
terminal differentiation programs in hair follicle keratinocytes.
These data provide an important foundation for further
research in identification of the mechanisms that trigger hair
follicle response to DNA damage and development of effec-
tive approaches for management of hair loss induced by anti-
cancer drugs.
RESULTS
Doxorubicin treatment induces apoptosis-driven premature
catagen development in human hair follicles cultured ex vivo
To further develop an ex vivo human model for chemother-
apy-induced hair loss used previously for studying hair
follicle response to cyclophosphamide (Bodo et al., 2007),
we focused our studies on doxorubicin (DXR), a broadly used
anti-cancer drug, treatment with which induces apoptosis in
hair follicles, followed by massive hair loss in patients as well
as in rodent models (Cece et al., 1996; Amoh et al., 2005;
Selleri et al., 2006; Amoh et al., 2007). In contrast to cyclo-
phosphamide, DXR does not require enzymatic conversion in
the liver to become active as an anti-cancer drug (Fraiser et al.,
1991; Siu et al., 1999), which we considered an advantage
that allows direct testing of its effects on hair follicles cultured
ex vivo.
To define whether DXR treatment is capable of inducing
apoptosis and premature catagen development in human hair
follicles cultured ex vivo, hair follicles isolated from the scalp
of normal individuals were cultured for 24 hours as described
previously (Bodo et al., 2007) followed by treatment with
different concentrations (0.3 or 1.0mM) of DXR for 1 hour
(Figure 1a). DXR concentrations for cultured hair follicles were
selected according to recommendations published previously
(Siu et al., 1999). Both DXR concentrations tested induced
rapid transition of normal anagen hair follicles into catagen
II/III stages within 24 hours after treatment (Figure 1b and c).
Treatment of hair follicles with 1.0mM DXR induced more
rapid catagen development compared with the group of
follicles treated with 0.3mM DXR (Figure 1c). After 5–7 days,
all hair follicles treated with both concentrations of DXR
entered catagen V–VI phase of the hair cycle, whereas about
67% of the follicles in the control group still remained in
anagen VI/catagen II phases (Figure 1b and c).
Analysis of the hair follicle apoptosis and cell proliferation
performed by double immuno-visualization of apoptotic
(TUNELþ ) and proliferating (Ki-67þ ) cells showed appear-
ance of numerous TUNELþ cells and significant decrease in
proliferating cells in the hair follicle matrix within 24 hours
after DXR treatment (Figure 2a–c). Further increase in
TUNELþ cells was seen in catagen III/IV hair follicles 2–3
days after DXR treatment (Figure 2a and b). Consistently with
morphological data (Figure 1c), hair follicles treated with
1.0mm of DXR showed more rapid increase in the number
of TUNELþ cells and decrease in cell proliferation in the hair
matrix compared with the group of follicles treated with
0.3mM DXR (Figure 2b and c). However, whereas control hair
follicles showed the appearance of single TUNELþ cells
during hair follicle progression to catagen II/III stages only 5
days after beginning of the experiment, lack of TUNELþ cells
and numerous proliferating Ki-67þ cells were seen in the
control follicles at the beginning of the study (Figure 2a–c).
These data suggest that, similar to 4-hydroperoxycyclophos-
phamide (Bodo et al., 2007), DXR treatment induces pre-
mature apoptosis-driven catagen development in human hair
follicles cultured ex vivo, which is consistent with its effects
on the hair follicles observed in the in vivo rodent models or
in patients who had received anti-cancer therapy (Cece et al.,
1996; Amoh et al., 2005; Selleri et al., 2006; Amoh et al.,
2007).
Early-phase response of hair follicles to DXR includes
upregulation of pro-apoptotic FAS and TRAIL receptors and
KAP genes
To define the molecular mechanisms underlying the initiation
of the hair follicle response to DXR, hair bulbs of the follicles
cultured ex vivo were collected 3 hours after DXR treatment
and processed for RNA isolation followed by global micro-
array analyses with Affymetrix GeneChipSystem, as described
previously (Fessing et al., 2010). Microarray data were
validated by quantitative real-time reverse-transcriptase–PCR
(qRT-PCR) and immunohistology and revealed 2-fold and
higher changes in the expression of 504 genes in DXR-
treated hair follicles compared with controls (Figure 3a).
Genes that show changes in expression in the hair follicles
after DXR treatment were grouped into several functional
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categories, which encoded apoptosis/cell cycle regulators,
adhesion/extracellular matrix molecules, cytoskeletal proteins,
metabolic enzymes, and signaling/transcription regulators
(Figure 3a; Supplementary Tables S1 and S2 online).
Genes that are involved in the control of apoptosis were
subdivided into the categories of pro- and anti-apoptotic
regulators (Figure 3b and c; Supplementary Tables S1
and S2 online). Interestingly, among the group of genes
that encoded different pro-apoptotic regulators, several
tumor necrosis factor (TNF)-family apoptotic receptors and
their ligands including FAS, TNFRSF10A, TNFRSF10B
(tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) receptors 1 and 2, respectively), TNFSF10 (TRAIL),
and TNFSF15 showed marked upregulation in DXR-treated
hair follicles versus the controls (Figure 3b and d). Immuno-
histological and quantitative immunohistomorphometric ana-
lyses revealed that, after DXR treatment, markedly increased
expressions of TRAIL, TRAIL-R1, p53, and caspase-8 were
seen in the hair follicle compartments enriched either in
proliferating keratinocytes (distal hair matrix) or in post-mitotic
differentiating cells (proximal part or precortex of the hair
bulb) compared with controls (Figure 3b and d; Supple-
mentary Figure S1a and b online).
However, microarray data validated by qRT-PCR also
showed increased expression of anti-apoptotic markers
(BCL2, BCL2A1, BCL6B, BCL10, TNFRSF10D, CFLAR) in
DXR-treated hair follicles compared with controls (Figure 3b
and d). This was not surprising because hair follicles contain
the significant number of cells that survive after chemother-
apy, including the dermal papilla fibroblasts, post-mitotic
differentiating keratinocytes, as well as epithelial progenitor
cells protected from apoptosis (Paus et al., 2013). Quantitative
immunohistomorphometric data revealed that one of the anti-
apoptotic regulators, cFLIP (CFLAR), that inhibit TNF receptor-
mediated apoptosis and caspase-8 activity (Kavuri et al., 2011)
is strongly upregulated in post-mitotic differentiating cells of
the inner root sheath and hair shaft (precortex area), as well as
in the dermal papilla, whereas its expression is detected at low
levels in proliferating hair matrix keratinocytes located at the
bottom of the hair bulb (Figure 3d; Supplementary Figure S1a
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Figure 1. Doxorubicin induces premature catagen development in human HFs cultured ex vivo. (a) Scheme illustrating the experimental design of this
study. (b) Morphological changes in HFs treated with 1mM doxorubicin (DXR) for 1 hour at different time points after treatment. Bars¼300mm and 100mm.
(c) Dynamics of catagen development in HFs treated with 0.3 or 1mM doxorubicin versus the controls (mean±SD, *Po0.05, Student’s t-test). CH, club hair;
DP, dermal papilla, DXR, doxorubicin; ES, epithelial strand; HF, hair follicle; HM, hair matrix.
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and b online). Because cFLIP expression decreased in differ-
entiating hair bulb keratinocytes 48 and 72 hours after DXR
treatment (Supplementary Figure S2 online), these data suggest
that the balance of pro- and anti-apoptotic regulators at early
time points after chemotherapy (3–24 hours) is critical for the
fate (apoptosis versus survival) of distinct hair follicle cell
populations (proliferating versus differentiating keratinocytes).
In addition to changes in expression of apoptosis-related
genes, two key genes that encode cell cycle inhibitors and
promote cell differentiation in the hair follicle (Scheitz and
Tumbar, 2013), such as cyclin-dependent kinase inhibitors
CDKN1A (P21) and CDKN1C (P57), also showed marked
upregulation in the hair follicle after DXR treatment
(Figure 3d; Supplementary Tables S1 and S2 online). Further-
more, DXR treatment resulted in upregulation of expression of
15 genes encoding keratin-associated proteins (KAPs; such as
KRTAP9-9, KRTAP4-7, KRTAP3-2, KRTAP1-3 and others) and
involved in execution of the terminal differentiation program
in hair matrix keratinocytes (Figure 3c and d; Rogers et al.,
2006). Consistently with microarray and qRT-PCR data, hair
follicles treated with DXR showed earlier onset of expression
of KAP1 in differentiating hair matrix keratinocytes compared
with controls (Figure 3d). The increased expression of the
KAP genes was accompanied by downregulation of the
genes encoding selected keratins, including KRT17, KRT16,
KRTHA3B, and KRT6A/6B, after DXR treatment, compared
with controls (Supplementary Tables S1 and S2 online). These
data suggest that DXR induces marked changes in gene
expression in hair matrix keratinocytes, which include not
only pro- and anti-apoptotic genes but also marked reorgani-
zation of the cell differentiation program and premature
activation of the KAP genes.
Inhibition of TRAIL receptor signaling and caspase-8 results in
decrease in DXR-induced apoptosis in the hair follicles
To assess the impact of TRAIL receptor–mediated signaling in
the control of apoptosis induced by DXR in the hair follicles,
hair follicles were treated with TRAIL-neutralizing antibody for
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Figure 2. Increase in apoptosis and decrease in cell proliferation in the hair follicles treated with DXR. (a) Double immuno-detection of apoptotic (TUNELþ ,
green arrowhead) and proliferating (Ki-67þ , red arrow) cells in the HFs treated with DXR versus controls. Scale bar¼ 100mm. (b) Increase in the number of
TUNELþ cells in the HFs exposed to 0.3 or 1mM DXR (mean±SD, ***Po0.001, Student’s t-test). (c) Decrease in the number of Ki-67þ cells in the HFs exposed
to 0.3 or 1mM DXR (mean±SD, *Po0.05, **Po0.01, Student’s t-test). DAPI, 4,6-diamidino-2-phenylindole; DXR, doxorubicin; HF, hair follicle.
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24 hours prior to and after DXR treatment. TRAIL-neutralizing
antibody has been shown previously to effectively inhibit
apoptosis in different models (Murata et al., 2006; Cantarella
et al., 2010). Treatment of follicles with TRAIL-neutralizing
antibody alone did not result in any significant changes in
keratinocyte proliferation or apoptosis, whereas expression of
TRAIL in the hair matrix was markedly decreased, suggesting
the inhibition of TRAIL activity (data not shown). However,
hair follicles treated with a combination of DXR and TRAIL-
neutralizing antibody showed marked decrease in the number
of TUNELþ cells compared with the follicles treated with
DXR alone, suggesting that DXR-induced apoptosis in hair
matrix keratinocytes is mediated, at least in part, by TRAIL
receptor signaling (Figure 4a–c). Furthermore, pretreatment
of hair follicles with TRAIL-R1 and TRAIL-R2 antagonistic
antibodies results in significant decrease in the number of
TUNELþ cells in the hair bulb after DXR treatment
(Figure 4d), suggesting that both TRAIL-R1 and TRAIL-R2 are
involved in mediating DXR-induced apoptosis in hair matrix
keratinocytes.
Because activation of the TRAIL receptor pathway is
accompanied by the recruitment of the adaptor protein FADD
and procaspase-8 to the intracellular death domain of the
receptors, followed by procaspase-8 cleavage and activation
of the effector caspases (Bremer et al., 2006), the effects of
caspase-8 inhibitor on DXR-induced apoptosis in the hair
follicle were tested. Similarly to the TRAIL-neutralizing
antibody, treatment of hair follicles with caspase-8 inhibitor
resulted in significant decrease in the number of TUNELþ
cells in DXR-treated hair follicles compared with the follicles
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Figure 3. Microarray, quantitative real-time reverse-transcriptase–PCR (qRT-PCR), and immunohistochemical profiling of human hair follicles 3–24 hours
after doxorubicin treatment. (a) Microarray analysis of the global gene expression in hair follicles (HFs) collected 3 hours after 1mm doxorubicin treatment
versus control HFs: functional assignments of the genes with altered expression induced by DXR. (b, c) Validation of microarray results by qRT-PCR
reveals changes in expression of the genes encoding distinct pro- and anti-apoptotic markers (b) (left and right panels, respectively) and cell differentiation–
associated markers (c) after doxorubicin treatment compared with controls. (d) Increase in expression of P53, FAS, TRAIL, TRAIL-R1, caspase-8, cFLIP, P21,
and KAP1 in the epithelial (arrows) or mesenchymal (asterisks) portions of the hair bulb 24 hours after doxorubicin treatment. Note, lack of cFLIP expression
in hair matrix keratinocytes located at the bottom part of the hair bulb (arrowheads), whereas prominent cFLIP expression is seen in the differentiating hair
shaft keratinocytes (arrow) and dermal papilla (asterisk). Scale bar¼ 100mm.
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treated with DXR alone (Figure 4a–c). These data suggest that
apoptosis induced by DXR in the hair follicles is mediated, at
least in part, by the TRAIL receptor 1/2 signaling involving an
activation of caspase-8 as its downstream effector.
DISCUSSION
Chemotherapy has severe side effects for normal rapidly
proliferating tissues, such as hair follicles, leading to massive
apoptosis in hair matrix keratinocytes followed by hair loss
(Paus and Cotsarelis, 1999; Botchkarev, 2003; Hendrix et al.,
2005; Paus et al., 2013). Because of the ethical issues in
obtaining scalp biopsies from patients treated with chemo-
therapy, only limited information is available about the mole-
cular events underlying the response of human hair follicles to
chemotherapy (Paus et al., 2013). Significant advantages in
this area were achieved by using isolated human hair follicles
cultured ex vivo and exposed to chemotherapy (Bodo et al.,
2007).
Here, we used an ex vivo human model for chemotherapy-
induced hair loss (Bodo et al., 2007) and global microarray
profiling to study changes in the molecular signature of human
hair follicles during the early stages of their response to DXR, a
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Figure 4. TRAIL or TRAIL-R1/R2 antagonistic antibodies and caspase-8 inhibitor decrease apoptosis in the hair follicles treated with doxorubicin (DXR).
HFs were treated with TRAIL-neutralizing antibody (5mg ml1), TRAIL-R1 or TRAIL-R2 antagonistic antibodies, or with caspase-8 inhibitor (50mm) for
24 hours prior to doxorubicin treatment. (a) Histomorphology of the HFs exposed for 48 hours to the different treatments. (b) Detection of apoptotic cells by
TUNEL (green) reveals numerous apoptotic cells in the HFs treated with doxorubicin (arrow). Scale bars¼100mm. (c) Quantitative analysis of apoptosis shows
dramatic elevation in TUNELþ cells in doxorubicin-treated HFs, whereas treatment with TRAIL-neutralizing antibody and caspase-8 inhibitor significantly
reduced doxorubicin-induced apoptosis (mean±SD, ***Po0.001 Student’s t-test). (d) Treatment with TRAIL-R1 or TRAIL-R2 antagonistic antibodies significantly
reduced doxorubicin-induced apoptosis and number of TUNELþ cells in the HFs (mean±SD, *Po0.05, **Po0.01, ***Po0.001; Student’s t-test).
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broadly used anti-cancer drug (Tacar et al., 2013). Cytotoxic
effects of DXR are based on its binding to and inhibiting
activity of the DNA-associated enzymes (topoisomerases I/II),
on intercalation with DNA base pairs, as well as on targeting
multiple apoptotic regulatory molecules such as Bcl2/Bax,
caspases, AMP-activated protein kinase, and so on (Tacar
et al., 2013). Consistently with the data obtained from tumor
cells, we demonstrate here that within 3 hours after DXR treat-
ment hair follicles show marked changes in the expression
levels of the genes encoding several components of the
apoptotic/cell cycle machinery, cytoskeleton/cell differentia-
tion markers, signaling/transcription regulators, and so on
(Supplementary Tables S1 and S2 online).
In general, these data are consistent with those obtained in
the same model that show changes in expression of quite
similar groups of genes in the hair follicles 48 hours after
4-hydroperoxycyclophosphamide treatment (Bodo et al.,
2007). Indeed, several key regulators of apoptosis, cell differen-
tiation, and signaling/transcription, such as TNFRSF10B,
CDKN1A, FGF-18, or ID4, showed similar changes in their
expression in the hair follicles treated with either DXR
(Supplementary Tables S1 and S2 online) or 4-hydroperoxy-
cyclophosphamide (Bodo et al., 2007). However, the
differences between the two data sets are also evident and
most likely reflect the distinct mechanisms of the DNA damage
response activated by DXR versus 4-hydroperoxycyclophos-
phamide, as well as the distinct time points in response to the
treatment (early versus more advanced) selected for analyses
(Bodo et al., 2007).
Interestingly, among the genes encoding pro-apoptotic
regulators, several members of the TNF family of apoptotic
receptors (FAS, TRAIL receptors 1 and 2) show upregulation in
their expression after DXR treatment. FAS as a direct p53
target gene is involved in the control of apoptosis induced by
chemotherapy in many organs, including hair follicles (Friesen
et al., 1996; Muller et al., 1997; Botchkarev et al., 2000;
Sharov et al., 2003; 2004). Similarly to FAS receptor, signaling
through TRAIL receptor 1/2 activated by the TRAIL ligand
induces apoptosis in normal and transformed keratinocytes
(Leverkus et al., 2000; Kavuri et al., 2011). Expression of the
TRAIL receptors 1/2 in tumor cells is increased after DXR
treatment (Wu et al., 2007). Apoptotic signaling through the
FAS and TRAIL receptors requires their interaction with the
intracellular adaptor molecule FADD, followed by activation
of procaspase-8, its recruitment into the death-inducing
signaling complex, and activation of caspase-3 along the
common final pathway of apoptosis (reviewed in Curtin and
Cotter, 2003; Peter and Krammer, 2003; Botchkareva et al.,
2006).
We show here that, similarly to tumor cells, DXR treatment
results in upregulation of TRAIL receptor 1 and 2 expressions
in the hair matrix keratinocytes, whereas treatment of
hair follicles with TRAIL-neutralizing antibodies or TRAIL-
R1/R2 antagonistic antibodies markedly reduces a number
of TUNELþ cells in the hair follicles (Figures 3b, c and 4).
Because TRAIL and TRAIL-R1 are direct p53 target genes
(Liu et al., 2004; Kuribayashi et al., 2008), TRAIL receptor–
mediated apoptosis is likely to be a part of the p53-regulated
apoptotic program triggered by DXR in hair matrix keratino-
cytes. However, because in some cases the increase in TRAIL-
R1/2 expression in tumor cells after chemotherapy occurs also
in a p53-independent manner (Cheng et al., 2012), further
studies are required to define the contribution of p53 to
upregulation of TRAIL receptors in the hair follicles after DXR
treatment. In addition, genetically engineered mice with
ablation of TRAIL-R1 or TRAIL-R2 might be used to further
dissect the role of these receptors in the control of
chemotherapy-induced apoptosis in hair matrix keratinocytes.
However, DXR treatment also increases the expression of a
number of anti-apoptotic genes in the hair follicle, which is
consistent with the data showing that distinct hair follicle cell
populations (selected outer root sheath and hair matrix
keratinocytes, dermal papilla fibroblasts) characterized by
high expression of anti-apoptotic proteins are programed to
survive after chemotherapy and contribute to subsequent hair
follicle regeneration (Lindner et al., 1997; Bodo et al., 2007;
Paus et al., 2013). One of such proteins, cFLIP, is capable of
inhibiting caspase-8 activation and apoptosis in keratinocytes
mediated by the TRAIL or FAS receptors (Kavuri et al., 2011).
As cFLIP is strongly upregulated in the post-mitotic differen-
tiating keratinocytes and is not expressed in proliferating hair
matrix keratinocytes, these data confirm the previously
proposed model suggesting that the balance of pro- and
anti-apoptotic factors has a critical role in the control of cell
fate decision (apoptosis versus survival) in the distinct hair
follicle cell populations after chemotherapy (Lindner et al.,
1997; Bodo et al., 2007; Paus et al., 2013).
Our data also reveal marked upregulation of 15 genes
encoding KAPs in the hair follicles after DXR treatment
(Figure 3b and c). In normal human hair follicles, KAPs are
expressed in differentiating keratinocytes of the hair matrix,
cortex, and cuticle (Rogers et al., 2006), whereas DXR treat-
ment leads to premature activation of KAP genes, as evident
by the KAP1 expression in post-mitotic hair matrix keratino-
cytes (Figure 3c). As recent data reveal that KAPs interact with
hair-specific keratins (Matsunaga et al., 2013), it appears to be
interesting to check whether premature activation of KAP
genes and early onset of expression of KAPs in the hair
follicles after DXR treatment have a role in alterations in the
hair shaft structure and breakage during chemotherapy-
associated anagen effluvium (Paus et al., 2013).
Interestingly, increase in KAP1 expression in the hair matrix
keratinocytes after DXR treatment coincides with upregulation
of P21 cyclin–dependent kinase inhibitor, a key p53 target
gene that promotes mitotic exit and terminal differentiation in
hair follicle keratinocytes (Mitsui et al., 2001; Lee et al., 2013).
In addition, microarray analyses reveal marked increase in
expression of the related CDKN1C (P57) gene in DXR-treated
follicles (Supplementary Table S1 online). Thus, it would be
interesting to test whether P21 and P57 contribute to marked
upregulation of the KAP genes in the hair follicle after DXR
treatment, or whether other mechanisms are involved in
mediating these effects of DXR.
Taken together, these data provide insights into the mechan-
isms underlying the early events in the complex changes
induced in human hair follicles by DXR and reveal a new role
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for TRAIL receptor signaling in the control of chemotherapy-
induced hair loss. These data also serve as an important
platform for the development of approaches for the prevention
or reduction of the toxic effects of chemotherapy on hair
follicles and for the search for drug-specific hair-protective
paradigms for cancer patients.
MATERIALS AND METHODS
Hair follicle culture and pharmacological experiments
This study was approved by the Institutional Review Board Commit-
tee of Boston University to ensure subject protection and adherence
to the Declaration of Helsinki Principles. Patient consent for experi-
ments was not required because human scalp skin samples were
obtained from anonymous donors (five different female individuals)
undergoing face-lift cosmetic surgery procedures. The hair follicles
were microdissected from skin samples and cultured in Williams E
medium supplemented with 10mg ml 1 insulin, 10 ng ml 1 hydro-
cortisone, 2 mM L-glutamine, and antibiotic/antimycotic mixture as
described previously (Philpott et al., 1994). Individual hair follicles
were cultured in 0.5 ml of supplemented Williams E medium at 37 1C
in a 5% CO2. After 24 hours of culture, DXR HCl (0.3 or 1.0mM;
Thermo Fisher Scientific, Waltham, MA) was added to the micro-
dissected anagen hair follicles for 1 hour, and culture medium was
replaced with freshly prepared supplemented Williams E medium
after completion of the DXR treatment. Control hair follicles were
treated with phosphate-buffered saline instead of DXR. For pharmaco-
logical modulation of apoptosis induced by DXR, hair follicles
were treated with TRAIL-neutralizing antibody (5mg ml 1, Abcam,
Cambridge, MA) or Caspase-8 inhibitor (50mM, Santa Cruz Biotech,
Dallas, TX), TRAIL-R1 and TRAIL-R2 mAbs (clones HS101 and
HS201, respectively, 10mg ml 1, Enzo Biochem, Farmingdale, NY),
and corresponding isotype-matched Ig for 24 hours prior to DXR
exposure. For each time point, 20–25 hair follicles from five
individuals were studied.
Microarray and qRT-PCR analyses
For microarray analysis, hair bulbs were dissected and processed for
RNA isolation 3 hours after completion of the DXR treatment. Total
RNA was isolated from the hair follicle bulbs using TriIzol reagent
(Invitrogen, San Diego, CA). All experiments were performed using at
least three replicates, and total RNA isolated from three experimental
and control samples was pooled and processed for microarray
analyses using one sample of pooled RNA per experimental
and control group. All microarray analyses were performed at the
Microarray Core Facility at Boston University School of Medicine
using Human Genome U133A 2.0 array (Affimetrix, Santa Clara, CA).
After statistical analysis and initial filtering of the microarray data the
changes in gene expression after DXR treatment equal to or 2-fold
higher with at least one signal equal to or higher than 80 fluorescence
units for the gene were considered significant (Fessing et al., 2010).
For quantitative RT-PCR analysis, equal amounts of total RNA were
used as a template for cDNA synthesis using SupperScript III First-
Strand Synthesis System and random primers (Life Technologies, San
Diego, CA). PCR primers were designed using Beacon Designer
software (Premier Biosoft International, Paolo Alto, CA) and are listed
in Supplementary Table S3 online. Real-time PCR was performed
using iCycler Thermal Cycler (Bio-Rad, Hercules, CA). Differences
between samples and controls were calculated using the Gene
Expression Macro program (Bio-Rad) based on the DDCt equitation
method, as described previously (Sharov et al., 2005; Sharov et al.,
2006; Fessing et al., 2011).
Immunohistochemistry and quantitative
immunohistomorphometry
For qRT-PCR, histomorphology, and immunohistochemical analyses,
hair follicles were collected at 3, 24, 48, 72 hours and 7 days after
DXR treatment. For immunohistochemical analyses, 8mm longitudi-
nal cryosections of the hair follicles taken through the central part of
the dermal papilla were used, as described previously (Botchkareva
et al., 2007). The cryosections were incubated with primary antisera
(see Supplementary Table S4 online) overnight at room temperature,
followed by application of corresponding TRITC- or Alexa Fluor 555
Conjugate-labeled secondary antibody (Invitrogen, Paisley, UK;
diluted 1:200) for 45 min at 37 1C. Incubation steps were interspersed
by four washes with phosphate-buffered saline (5 minutes each), as
described previously (Muller-Rover et al., 1998; Botchkarev et al.,
1999; Siebenhaar et al., 2007). For double immunofluorescence
detection of TUNEL-positive cells and Ki-67 immunoreactivity, the
ApopTag Fluorescein Direct In Situ Apoptosis Detection Kit (EMD
Millipore, Billerica, MA) and anti Ki-67 antibody were used.
Alkaline phosphatase staining was used for identification and
quantification of the hair follicles at distinct stages of catagen, as
described previously (Hendrix et al., 2005). Ki67þ cells were
calculated below the distal end of the dermal papilla and were
expressed as percentage to the total number of DAPIþ cells in the
hair matrix, whereas TUNELþ cells were calculated per hair bulb,
according to recommendations published previously (Bodo et al.,
2007). In total, 20–25 hair follicles were assessed per time point in
each experimental and control group. Image preparation and analysis
were performed using a fluorescent microscope (Nikon, Tokyo, Japan)
in combination with a DS-C1 digital camera and ACT-2U image
analysis software (Nikon).
Immunofluorescence intensity was determined using ImageJ soft-
ware (NIH, Bethesda, MD), as described previously (Ramot et al.,
2010). In brief, red fluorescent signal was collected from
experimental tissues in RGB format under the same exposure
conditions. To measure the fluorescence intensity at each pixel, the
RGB images were converted to 8-bit grayscale format. Regions of
interest of distinct size (hair matrix—170mm2, dermal papilla—
180mm2, and pre-cortex—200mm2) within the control and DXR-
treated hair follicles were selected, and the mean values of intensity
(the sum of gray values of all the pixels in the selection divided
by the number of pixels) were calculated for each selected area.
In total, 20–25 hair follicles were assessed per time point for
each marker (TRAIL, TRAIL-R1, cFLIP) in the DXR-treated and
control groups, and the differences between mean values obtained
from the control and DXR-treated hair follicles were calculated using
Student’s t-test.
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